Pauline De Breteuil

Sleep is one of healthcare’s biggest blind spots. Access is slow, confusing and uneven, and millions of people who need help never get it. Sunrise exists to change that. Born from pioneering research on mandibular jaw movement, we built a chin-based sleep test that reinvented how sleep disorders can be diagnosed from home. That breakthrough has evolved into a full sleep-health platform: advanced diagnostic and treatment technology paired with clinical care delivered directly to patients’ homes through Dreem Health in all 50 U.S. states. Across the U.S. and Europe, our 100+ clinicians, engineers and operators share one mission: make high-quality sleep care accessible to everyone. Backed by more than $50M, we’re taking on one of healthcare’s biggest challenges: the 1+ billion people worldwide who still can’t get the sleep care they need.

AlgoTx is a clinical stage biotechnology company developing targeted, first in class therapeutics for peripheral neuropathic pain. Non-opioid, locally acting ATX01 is designed to treat the pain of Chemotherapy-Induced Peripheral Neuropathy, a common and painful side-effect of cancer treatments. It targets the signaling pathways involved in the regulation of pain by selectively inhibiting specific nociceptive sodium channel receptors. FDA granted ATX01 Fast-Track designation. The ACT study is an international Phase II randomized, placebo-controlled trial involving over 270 patients ; The results will be available in early 2025 and the company is making plans to expedite a Phase 3 trial. The company has seasoned leadership, with experience of bringing global products successfully to market, and is backed by an international board. AlgoTx raised a Series B round of EUR 20 million in 2023 and has raised EUR 35 million to date. AlgoTx has a consortium of investors including Relyens Innovation Santé / Turenne Capital, who led the Series B fund raise, along with UI Investissement, and angel investors. Historical investors include Bpifrance through its Innobio 2 fund and Omnes Capital. In 2023, the company won France Biotech’s prestigious ESG HealthTech Trophy in recognition of its early commitment to ESG initiatives. For more information, see the company’s website

NaoX Technologies est une startup française lancée en 2018 par Hugo DINH, Polytechnicien et Michel LE VAN QUYEN, expert en neuroscience à lInserm. Notre mission est de démocratiser la prévention de troubles neurologiques.

Our mission is to Fix the broken link in the chain of survival by putting the P back in CPR. We provide high-performance Ventilation Feedback Devices (VFD) that empower emergency responders, hospitals, and military organizations with real-time feedback for high-quality manual ventilation, ensuring optimal care when it matters most. Archeon Medical offers two key devices: - EOlife: The only Ventilation Feedback Device (VFD) that measures the volume of gas reaching the patient’s lungs (Tidal volume), ensuring accurate and effective ventilation during critical care. CE-marked and FDA-cleared, EOlife offers visual feedback to deliver ventilation in accordance with ERC or AHA recommendations. - EOlife X: The ultimate tool for high-performance ventilation training, designed to provide hands-on experience in real-world scenarios, in accordance with ERC and AHA recommendations. EOlife X enables training on adult and pediatric (>1 year) manikins. At Archeon Medical, we believe in transforming manual ventilation into a life-saving standard. Together, let’s make every breath count in CPR.

i-Virtuals mission is to democratize remote, touchless vital sign measurement, making it accessible to industries across the board and transforming how vital health information is captured and leveraged. As leaders in signal processing, computer vision, and artificial intelligence, i-Virtual has developed innovative technology that enables vital sign measurements through a simple, contactless process. We were the first in the world to receive CE Class IIa certification for a medical device that captures key physiological data—including heart rate, heart rate variability, breathing rate, and stress level—from a 30-second video selfie. This list will continue to grow as we further enhance our technology and enter new markets. We are now expanding our offering with a powerful API, enabling application and platform developers across various industries to integrate our technology with shorter time-to-market and less overhead. This empowers developers to significantly enhance their solutions with touchless vital sign measurement capabilities, while making health data more accessible and actionable across diverse markets.

Sancare leverages NLP, Machine Learning and AI to serve healthcare. Our cutting-edge solutions aim to improve patient care while reducing costs.

Sym réinvente le parcours de santé optique de la prescription à la délivrance de lunettes. Notre objectif est d’offrir le meilleur service de santé optique possible, accessible à tous avec une approche intégrée et novatrice. Sym est le seul service en France à offrir un examen de vue gratuit avec émission d’ordonnance et les meilleures lunettes du marché sans avance de frais et sans reste à charge. Le tout en une seul visite de 30 minutes dans nos points de vente éphémères et itinérants.

GLEAMER offers a suite of AI solutions for radiology that encapsulate medical-grade expertise. Our company wants to support imaging readers to secure diagnoses for all patients at all times while improving comfort and workflow efficiency. Our team imagines and develops solutions booth at the level of an expert and is easy to integrate thanks to the joint work of a multi-disciplinary team encapsulating AI and radiologist experts. GLEAMER has already been integrated into more than 650 institutions in each part of the world. 🏅Alexander Margulis award - Scientific excellence for the BoneView clinical study 🏅 🏅 2023 Eurominnies awards - Best New Radiology Vendor🥇

Streamline access, organization, and sharing of medical data to enhance the quality of care and clinical research.

Epigene Labs is creating the intelligence-augmenting solution for precision oncology research and drug development. Designed by cancer scientists for cancer scientists, the company's mCUBE platform accelerates data-driven drug discovery, biomarker identification, and patient selection -- to bring better treatments to patients faster. Based in Paris and Boston, Epigene Labs was initially incubated at the Harvard Innovation Labs and launched in France with the support of prominent European investors. Epigene Labs has partnerships with world-class cancer research institutes and biopharmaceutical companies.

VA2CS souhaite moderniser la téléassistance ou les systèmes d’appels malade en apportant une solution pour laquelle il n’y à rien a porter, rien à appuyer mais offrant une grande précision et une rapidité d’analyse de situations à risque et avec levée de doute. Des capteurs optiques avec un traitement d’image local permettent d’interpréter immédiatement et automatiquement les situations à risque (Brevet déposé) We modernize teleassistance & nurse call systems by bringing a solution where - with nothing to wear & nothing to press – falls and risky situations can be automatically detected with, in addition, an image base check capacity to avoid doubt when needed. VA2CS technology: Optical sensors combined with local image processing (proprietary algorithm) automatically detect falls and risky situations (Registered patent) and alert carers.

VA2CS souhaite moderniser la téléassistance ou les systèmes d’appels malade en apportant une solution pour laquelle il n’y à rien a porter, rien à appuyer mais offrant une grande précision et une rapidité d’analyse de situations à risque et avec levée de doute. Des capteurs optiques avec un traitement d’image local permettent d’interpréter immédiatement et automatiquement les situations à risque (Brevet déposé) We modernize teleassistance & nurse call systems by bringing a solution where - with nothing to wear & nothing to press – falls and risky situations can be automatically detected with, in addition, an image base check capacity to avoid doubt when needed. VA2CS technology: Optical sensors combined with local image processing (proprietary algorithm) automatically detect falls and risky situations (Registered patent) and alert carers.

Créée en 2012, la société Medylink propose aux médecins généralistes une gamme de services pour la coordination des soins via une plateforme disponible en mode SaaS (software as a service). Elle comprend la mise en relation avec des spécialistes ou des infirmiers à qui le médecin pourra déléguer certains actes, une assistance administrative, et la possibilité de louer du matériel de dépistage et de diagnostic (électrocardiogramme, spiromètre, holter, polygraphie, rétinographie, etc.) et d'être formés à son utilisation.

Majycc Innovation Santé est un fonds d’investissement « venture capital », dédiée à l’investissement dans les start up de la e.santé appartenant à la société de gestion UI Investissement. Les grands sponsors de Majycc : Yves Journel, le fondateur d’SRS (Sagesse Retraite Santé), dont nous sommes issus, est reconnu comme un acteur incontournable dans le secteur sanitaire et médico-social. Notre connaissance métier et notre réseau santé sont donc inégalables. Nous nous engageons pour les entrepreneurs qui veulent être les architectes de la santé de demain. Notre approche s’inscrit dans la durée et notre motivation tient avant tout de la volonté d’accompagner et d’aider durablement au développement des entreprises qui veulent redonner du sens à la santé. Notre expertise dans le digital, nous permet de bien comprendre comment les startups contribuent à transformer nos métiers de la santé et à mettre cette expertise et notre réseau digital (marketing, commercial, RH …) au service de nos participations. Nos racines sont liées à l’ADN d’SRS, notre investisseur principal : entrepreneuriat, santé et valeurs humaines, respect de la culture des entreprises et des projets des femmes et hommes qui les bâtissent.

Coave Therapeutics is a clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases. We are pushing the boundaries of gene therapy through application of our AAV-Ligand Conjugates platform (ALIGATER) that enables targeted delivery, enhanced gene transduction and tissue distribution to improve the effectiveness of advanced gene therapies for rare diseases. Our strategy is to advance a pipeline of novel therapies targeting rare ocular and CNS diseases where targeted gene therapy has the potential to be most effective, where there is a clear unmet need and where success will provide rapid validation of our ALIGATER platform.

Sleep is one of healthcare’s biggest blind spots. Access is slow, confusing and uneven, and millions of people who need help never get it. Sunrise exists to change that. Born from pioneering research on mandibular jaw movement, we built a chin-based sleep test that reinvented how sleep disorders can be diagnosed from home. That breakthrough has evolved into a full sleep-health platform: advanced diagnostic and treatment technology paired with clinical care delivered directly to patients’ homes through Dreem Health in all 50 U.S. states. Across the U.S. and Europe, our 100+ clinicians, engineers and operators share one mission: make high-quality sleep care accessible to everyone. Backed by more than $50M, we’re taking on one of healthcare’s biggest challenges: the 1+ billion people worldwide who still can’t get the sleep care they need.

AlgoTx is a clinical stage biotechnology company developing targeted, first in class therapeutics for peripheral neuropathic pain. Non-opioid, locally acting ATX01 is designed to treat the pain of Chemotherapy-Induced Peripheral Neuropathy, a common and painful side-effect of cancer treatments. It targets the signaling pathways involved in the regulation of pain by selectively inhibiting specific nociceptive sodium channel receptors. FDA granted ATX01 Fast-Track designation. The ACT study is an international Phase II randomized, placebo-controlled trial involving over 270 patients ; The results will be available in early 2025 and the company is making plans to expedite a Phase 3 trial. The company has seasoned leadership, with experience of bringing global products successfully to market, and is backed by an international board. AlgoTx raised a Series B round of EUR 20 million in 2023 and has raised EUR 35 million to date. AlgoTx has a consortium of investors including Relyens Innovation Santé / Turenne Capital, who led the Series B fund raise, along with UI Investissement, and angel investors. Historical investors include Bpifrance through its Innobio 2 fund and Omnes Capital. In 2023, the company won France Biotech’s prestigious ESG HealthTech Trophy in recognition of its early commitment to ESG initiatives. For more information, see the company’s website

Spécialiste du développement des entreprises françaises non cotées, UI s’engage et s’investit, depuis plus de 50 ans, aux côtés de dirigeants de startups, PME et d’ETI en croissance pour faire émerger et développer des entreprises économiquement et durablement performantes. UI Investissement gère de lordre d’1,5 milliard d’euros d’actifs et s’investit auprès de 300 dirigeants dans des secteurs d’activité essentiels à la société comme la santé, l’agro-business ou l’industrie et les services. Le capital développement et transmission, cœur historique de l’activité d’UI représente plus de la moitié de l’actif sous gestion et permet de faire bénéficier plus de 50 entreprises de l’expertise opérationnelle et des outils méthodologiques développés par UI. En parallèle, les équipes et véhicules d’investissement dédiés à l’innovation et à la consolidation permettent d’accompagner les entreprises tout au long de leur cycle de vie et de contribuer au dynamisme économique des territoires. UI s’appuie aujourd’hui sur près de 80 collaborateurs et, en complément de ses équipes de Paris, sur plus de 10 implantations régionales (Besançon, Clermont-Ferrand, Dijon, Lille, Limoges, Lyon, Nantes, Orléans, Reims, Rennes, Strasbourg…).

NaoX Technologies est une startup française lancée en 2018 par Hugo DINH, Polytechnicien et Michel LE VAN QUYEN, expert en neuroscience à lInserm. Notre mission est de démocratiser la prévention de troubles neurologiques.